The Technology

A vaccine adjuvant is an agent that enhances the immune response to an antigen. Eurocine Vaccines has a proprietary adjuvant technology named Endocine™.

Endocine™ is based on endogenous lipids naturally found ubiquitously in the human body. When carefully processed, formulated and mixed with an antigen it enhances the immunological reaction against disease. The technology has been shown safe in five clinical trials and has been administered to more than 400 human subjects.
Due to its outstanding safety profile and unique formulation, Endocine™ may be reformulated together with existing vaccines or novel antigens in order to;

Enhance the immune response and provide immunity against antigens with low immunogenicity
Achieve an immunological and protective effect with a lower quantity of antigen and thus be antigen-sparing
Potentially confer an accelerated and/or prolonged immune response

Vaccine Applications

The adjuvant technology Endocine™ may be applied to a variety of vaccine antigens to enable stimulation of immunity using whole or split antigens, proteins or peptides.

Bacteria

Bacterial vaccines represent a huge market. The biggest of all vaccine products, Prevnar, prevents pneumococcal disease. In addition to existing vaccines on the market, there is an intense activity developing new vaccines against bacterial diseases, where Endocine may add to the success.

Virus

Vaccines have prevented much suffering from one of the recurring viral diseases, influenza, for a long period of time. Emerging viral diseases as well as viral diseases hitherto without prophylactic vaccines may represent promising candidates to combine with Endocine.

Cancer

In the mid to longer term, Endocine may bring value to the buoyant area of cancer vaccines by enhancing the immune responses.

Allergies

Allergy vaccines has a particular need for safety. The proven safety of Endocine may in the longer term add to such vaccines that need enhancement of the efficacy, without unwanted side effects.

Research & Publications

Intranasally administered Endocine™ formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
Maltais AK, Stittelaar KJ, Veldhuis Kroeze EJ, van Amerongen G, Dijkshoorn ML, Krestin GP, Hinkula J, Arwidsson H, Lindberg A, Osterhaus AD. Vaccine. 2014 May 30;32(26):3307-15. doi: 10.1016/j.vaccine.2014.03.061. Epub 2014 Mar 30.

Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
Falkeborn T, Bråve A, Larsson M, Akerlind B, Schröder U, Hinkula J. PLoS One. 2013 Aug 8;8(8):e70527. doi: 10.1371/journal.pone.0070527. eCollection 2013

The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
Pernilla Petersson, Mona Hedenskog, Denise Alves, Mia Brytting, Ulf Schröder, Annika Linde, Åke Lundkvist. Vaccine 28 (2010) 6491-6497

Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice.
Jorma Hinkula, Marie Hagbom, Britta Wahren, Ulf Schröder. Vaccine 26 (2008) 5101-5106

Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
Andreas Bråve, David Hallengärd, Ulf Schöder, Pontus Blomberg, Britta Wahren and Jorma Hinkula. Vaccine 26 (2008) 5075-5078

DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosalimmunity with cross-clade neutralizing activity.
L. Buonaguro, C. Devito, M.L. Tornesello, U. Schröder, B. Wahren, J. Hinkula and F.M. Buonaguro Vaccine 25 (2007) 5968-5977

A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations.
Jorma Hinkula, Claudia Devito, Bartek Zuber, Reinhold Benthin, Denise Ferreira, Britta Wahren, Ulf Schröder. Vaccine 24 (2006) 4494-4497

Nasal boost with adjuvanted heat killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice.
M. Haile, B. Hamasur, T. Jaxmar, D. Gavier-Widen, M.A. Chambers, B. Sanchez, U. Schröder, Källenius, S.B. Svenson, A. Pawlowski. Tuberculosis (2005) 85, 107-114Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen of mice results in longterm HIV-1 neutralizing humoral, mucosal and systemic immunity.
C. Devito, B. Zuber, U. Schröder, R. Benthin, K. Okuda, K. Broliden, B. Wahren and J. Hinkula. J.Immunology (2004) 173: 7078-7089

Immunization with heat-killed Mycobacterium bovis bacille Calmette–Guerin (BCG) in EurocineTM L3 adjuvant protects against tuberculosis.
M. Haile, U. Schröder, B. Hamasur, A. Pawlowski, T. Jaxmar, G. Källenius, S.B. Svenson. Vaccine 22 (2004) 1498-1508